Inclusion Criteria:~* Patient may be of either sex and must be supervised by a carer who is competent to ensure
compliance with the medication and who is willing to participate in completing the various assessments.~*
Patients must be able to give written informed consent to participate in this study. Patients who lack capacity
to consent may not be entered.~* Competent carer must be available and must provide written consent to his or
her own participation in the study.~* Clinical diagnosis of dementia of the Alzheimer type determined by
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria and a diagnosis of Probable Alzheimer's
Disease determined by the National Institute of Neurological and Communicative Disorders and Stroke -
Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. Information to support the
diagnosis will include that derived from:~ * an abbreviated Cambridge Mental Disorders of the Elderly
Examination (short CAMDEX) schedule, performed within six weeks prior to the baseline visit (Visit 0).~ *
Computerised tomography (CT) or magnetic resonance imaging (MRI), with no time limit on previous scans. In
centres conducting SPECT/PET scans as part of their routine practice or as part of the study these may be used
to inform the NINCDS-ADRDA diagnosis.~* Patient must have mild or moderate dementia as determined by:~ *
Mini-Mental State Examination (MMSE) value at screening of between 10 and 26 inclusive.~ * Clinical Dementia
Rating (CDR) at screening of Stage 1 or Stage 2.~
